{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:42:15Z","timestamp":1784191335340,"version":"3.55.0"},"reference-count":30,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2002,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Terbinafine, an allylamine used to treat onychomycosis, has been reported to be active against rat<jats:italic>Pneumocystis carinii<\/jats:italic>in vitro and in vivo. By contrast, our in vitro data showed that the 50% inhibitory concentration of terbinafine against rat<jats:italic>P. carinii<\/jats:italic>is 3.7 \u03bcg\/ml, a level that cannot be clinically achieved in serum. In the present study, terbinafine administered orally at doses of 20 to 400 mg\/kg\/day and 50 to 250 mg\/kg\/day was ineffective therapy for mouse and rat models of pneumocystosis, respectively. These results emphasize the complexities of<jats:italic>P. carinii<\/jats:italic>drug testing and the need for caution before considering studies in humans.<\/jats:p>","DOI":"10.1128\/aac.46.2.514-516.2002","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:06:42Z","timestamp":1027764402000},"page":"514-516","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":10,"title":["Use of Terbinafine in Mouse and Rat Models of<i>Pneumocystis carinii<\/i>Pneumonia"],"prefix":"10.1128","volume":"46","author":[{"given":"Peter D.","family":"Walzer","sequence":"first","affiliation":[{"name":"Research Service, Veterans Affairs Medical Center, Cincinnati, Ohio 45220"},{"name":"Division of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Ashbaugh","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.8.1834"},{"key":"e_1_3_2_3_2","first-page":"1580","volume":"60","year":"1992","unstructured":"Boylan, C. J., and W. L. Current. 1992. Improved model of Pneumocystis carinii pneumonia: induced laboratory infection in Pneumocystis-free animals. Infect. Immun.60:1580\u20131597.","journal-title":"Infect. Immun."},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/jac\/36.4.740","volume":"36","year":"1995","unstructured":"Cirioni, O., A. Giacometti, M. Balducci, F. Burzacchi, and G. Scalise. 1995. In-vitro activity of terbinafine, atovaquone and co-trimoxazole against Pneumocystis carinii. J. Antimicrob. Chemother.36:740\u2013742.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.4.806"},{"key":"e_1_3_2_6_2","first-page":"30","volume":"26","year":"1996","unstructured":"Contini, C., D. Colombo, R. Cultrera, E. Prini, T. Sechi, E. Angelici, and R. Canipari. 1996. Employment of terbinafine against Pneumocystis carinii infection in rat models. Br. J. Dermatol.26:30\u201332.","journal-title":"Br. J. Dermatol."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/jac\/34.5.727","volume":"34","year":"1994","unstructured":"Contini, C., M. Mangnaro, R. Romani, S. Tzantzoglou, I. Poggesi, V. Vulio, S. Delia, and C. De Simone. 1994. Activity of terbinafine against Pneumocystis carinii in vitro and its efficacy in the treatment of experimental pneumonia. J. Antimicrob. Chemother.34:727\u2013735.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.2.379"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1159\/000238485"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2340\/000155557300304","volume":"73","year":"1993","unstructured":"Faergemann, J., H. Zehender, J. Denouel, and L. Millerioux. 1993. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks. Acta Derm. Venereol.73:305\u2013309.","journal-title":"Acta Derm. Venereol."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.6.1309"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.1.172"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/infdis\/170.4.906","volume":"170","year":"1994","unstructured":"Hughes, W. T., J. T. Kilmar, and H. S. Oz. 1994. Relative potency of 10 drugs with anti-Pneumocystis activity in an animal model. J. Infect. Dis.170:906\u2013911.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/bdd.2510160807","volume":"16","year":"1995","unstructured":"Humbert, H., M. D. Cabiac, J. Denouel, and S. Kirkesseli. 1995. Pharmacokinetics of terbinafine and of its five main metabolites in plasma and urine, following a single oral dose in healthy subjects. Biopharm. Drug Dispos.16:685\u2013694.","journal-title":"Biopharm. Drug Dispos."},{"key":"e_1_3_2_15_2","first-page":"3437","volume":"10","year":"2001","unstructured":"Icenhour, C. R., S. L. Rebholz, M. S. Collins, and M. T. Cushion. 2001. Widespread occurrence of Pneumocystis carinii in commercial rat colonies detected using targeted PCR and oral swabs. J. Clin. Microbiol.10:3437\u20133441.","journal-title":"J. Clin. Microbiol."},{"key":"e_1_3_2_16_2","first-page":"1619","volume":"32","year":"1998","unstructured":"Kan, V. L., and J. E. Bennett. 1998. Efficacies of four antifungal agents in experimental murine sporotrichosis. Antimicrob. Agents Chemother.32:1619\u20131623.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.6.1630-1638.2000"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/315719"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.12.2738"},{"key":"e_1_3_2_20_2","first-page":"1327","year":"1997","unstructured":"Kucers, A., S. M. Crow, M. L. Grayson, and J. F. Hoy. 1997. The use of antibiotics, p.1327\u20131337. Butterworth-Heinemann, Oxford, England.","journal-title":"The use of antibiotics"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-081X(199703)18:2<127::AID-BDD6>3.0.CO;2-8"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01967386"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.11.3087-3091.2000"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.3.580"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1086\/314509"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.9.1943"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.2.242"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.2.251"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1086\/323991","volume":"184","year":"2001","unstructured":"Walzer, P. D., A. Ashbaugh, M. Collins, and M. T. Cushion. 2001. Anti-human immunodeficiency virus drugs are ineffective against Pneumocystis carinii in vitro and in vivo. J. Infect. Dis.184:1355\u20131357.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.11.3234-3237.2001"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/00034983.2000.11813603","volume":"94","year":"2000","unstructured":"Zakai, H. A., and S. K. Zimmo. 2000. Effects of itraconazole and terbinafine of Leishmania major lesions in BALB\/mice. Ann. Trop. Med. Parasitol.94:787\u2013791.","journal-title":"Ann. Trop. Med. Parasitol."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.46.2.514-516.2002","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.46.2.514-516.2002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T00:32:52Z","timestamp":1704501172000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.46.2.514-516.2002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["10.1128\/AAC.46.2.514-516.2002"],"URL":"https:\/\/doi.org\/10.1128\/aac.46.2.514-516.2002","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,2]]},"assertion":[{"value":"2001-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-10-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-02-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}